NO20092530L - Genetiske markorer for risikohandtering av hjertearrytmi - Google Patents

Genetiske markorer for risikohandtering av hjertearrytmi

Info

Publication number
NO20092530L
NO20092530L NO20092530A NO20092530A NO20092530L NO 20092530 L NO20092530 L NO 20092530L NO 20092530 A NO20092530 A NO 20092530A NO 20092530 A NO20092530 A NO 20092530A NO 20092530 L NO20092530 L NO 20092530L
Authority
NO
Norway
Prior art keywords
cardiac arrhythmia
atrial fibrillation
risk management
genetic markers
markers
Prior art date
Application number
NO20092530A
Other languages
English (en)
Inventor
Anna Helgadottir
Daniel Gudbjartsson
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IS8576A external-priority patent/IS8576A/is
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of NO20092530L publication Critical patent/NO20092530L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Oppfinnelsen vedrører fremgangsmåte og prosedyre for å bestemme en mottakelighet for hjertearytmi, inkludert atrieflimmer, atrieflutter og slag, ved å vurdere nærvær eller fravær av alleler ved polymorfe markører som man har funnet er assosiert med atrieflimmer, atrieflutter og slag. Oppfinnelsen vedrører ytterligere sett omfattende reagenser for vurdering av slike markører og diagnostiseringsfremgangsmåter, anvendelse og prosedyrer for å bruke slike mottakelighetsmarkører.
NO20092530A 2006-12-05 2009-07-03 Genetiske markorer for risikohandtering av hjertearrytmi NO20092530L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8576A IS8576A (is) 2006-12-05 2006-12-05 Genetic susceptibility variants of atrial fibrillation and stroke
IS8658 2007-06-29
PCT/IS2007/000021 WO2008068780A2 (en) 2006-12-05 2007-12-05 Genetic markers for risk management of cardiac arrhythmia

Publications (1)

Publication Number Publication Date
NO20092530L true NO20092530L (no) 2009-09-03

Family

ID=39133840

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092530A NO20092530L (no) 2006-12-05 2009-07-03 Genetiske markorer for risikohandtering av hjertearrytmi

Country Status (15)

Country Link
US (2) US8637244B2 (no)
EP (1) EP2121979B1 (no)
JP (1) JP5646174B2 (no)
KR (2) KR101582321B1 (no)
AU (1) AU2007330306B2 (no)
BR (1) BRPI0720116B8 (no)
CA (1) CA2673123C (no)
DK (1) DK2121979T3 (no)
EA (1) EA017529B1 (no)
IL (1) IL199049A (no)
MX (1) MX2009005651A (no)
NO (1) NO20092530L (no)
NZ (1) NZ577805A (no)
SG (1) SG177185A1 (no)
WO (1) WO2008068780A2 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720116B8 (pt) * 2006-12-05 2021-07-27 Decode Genetics Ehf método para determinar uma suscetibilidade à arritmia cardíaca ou acidente vascular cerebral em um indivíduo humano, uso de uma sonda de oligonucleotídeo, e, aparelho para determinar um indicador genético para a arritmia cardíaca e/ou acidente vascular cerebral em um indivíduo humano
CA2751090A1 (en) * 2009-01-30 2010-08-05 Electrophoretics Limited Method for the in vitro diagnosis of stroke
EP2414543B1 (en) * 2009-04-03 2016-10-12 Decode Genetics EHF Genetic markers for risk management of atrial fibrillation and stroke
US20120264636A1 (en) * 2009-10-07 2012-10-18 Decode Genetics Ehf. Genetic variants indicative of vascular conditions
AU2011227108A1 (en) * 2010-03-19 2012-10-11 Cardiodx, Inc. Determining susceptibility to a sudden cardiac event
WO2011153428A1 (en) * 2010-06-03 2011-12-08 Medtronic, Inc. System and method for assessing a likelihood of a patient to experience a future cardiac arrhythmia using dynamic changes in a biological parameter
WO2012000119A1 (en) * 2010-07-02 2012-01-05 Prognomix Inc. A method of determining a predisposition to atrial fibrillation in a subject
US8715646B2 (en) * 2010-07-29 2014-05-06 The Board Of Trustees Of The University Of Illinois Methods of determining need for anti-coagulation therapy
KR101230088B1 (ko) * 2010-11-24 2013-02-05 연세대학교 산학협력단 심방세동의 예후 예측 방법
KR101331787B1 (ko) * 2011-10-04 2013-11-21 한국과학기술연구원 심장 부정맥 진단용 바이오마커 및 이를 이용한 심장 부정맥 진단 방법
EP3088900B1 (en) 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin as marker for intermittent atrial fibrillation
US20140364334A1 (en) * 2011-12-21 2014-12-11 Nuclea Biotechnologies, Inc. Congestive heart failure biomarkers
BR112014024537A2 (pt) 2012-04-02 2017-08-08 Berg Llc métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
KR101462006B1 (ko) * 2013-07-23 2014-11-18 한국과학기술연구원 심장 부정맥 진단용 바이오마커 및 이를 이용한 심장 부정맥 진단 방법
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
CA2960837A1 (en) * 2014-09-11 2016-03-17 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
US10678367B1 (en) * 2015-09-11 2020-06-09 Apple Inc. Compressive touch sensing
CA2999890A1 (en) * 2015-09-24 2017-03-30 Caris Science, Inc. Method, apparatus, and computer program product for analyzing biological data
KR101883657B1 (ko) * 2016-05-13 2018-07-31 연세대학교 산학협력단 단일염기다형성에 의한 심방세동의 예측 또는 진단에 관한 정보 제공 방법
RU2657942C1 (ru) * 2017-07-25 2018-06-18 Федеральное государственное бюджетное образовательное учреждение высшего образования Читинская государственная медицинская академия Министерства здравоохранения российской федерации Способ прогнозирования риска развития фибрилляции предсердий у женщин с ишемической болезнью сердца
RU2664430C1 (ru) * 2017-12-14 2018-08-17 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития инсульта у мужчин на основе генетического тестирования
CN109324189B (zh) * 2018-08-15 2021-10-01 泰达国际心血管病医院 多蛋白组合物的应用及先天性心脏病筛查试剂盒
US12419863B2 (en) 2018-11-02 2025-09-23 Celltrion Inc. Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
US12117453B2 (en) 2018-12-07 2024-10-15 Washington University Predicting patient response to sodium channel blockers
JP7165100B2 (ja) * 2019-04-23 2022-11-02 ジェネシスヘルスケア株式会社 心房細動及び／又は心室細動のリスクを判定する方法
US20230002829A1 (en) * 2019-12-13 2023-01-05 Ischemia Care Llc Biomarkers for the diagnosis of atrial fibrillation cause of stroke
KR102250719B1 (ko) * 2020-01-07 2021-05-11 고려대학교 산학협력단 발작성 심방세동 환자의 재발 위험도 예측을 위한 바이오 마커
US20230332236A1 (en) * 2020-10-08 2023-10-19 Ischemia Care Llc Method for diagnosing stroke utilizing gene expression signatures
CA3192122A1 (en) * 2020-10-20 2022-04-28 Kevin Wong Methods of assessing risk of developing a disease
MX2023011037A (es) * 2021-03-19 2023-09-27 Changchun Jetty Automotive Tech Co Ltd Circuito guia de control de carga y toma de carga.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS60501339A (ja) * 1983-01-10 1985-08-22 ジエン−プロ−ブ　インコ−ポレィテッド 生物を検出、同定又は定量する方法およびキット
US5288611A (en) * 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5288644A (en) * 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0562025T3 (da) 1990-12-06 2001-06-18 Affymetrix Inc Forbindelser og deres anvendelse i en binær syntesestrategi
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
CA2134552A1 (en) 1992-04-27 1993-11-11 George D. Sorenson Detection of gene sequences in biological fluids
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
WO2004028341A2 (en) * 2001-03-19 2004-04-08 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
BRPI0720116B8 (pt) * 2006-12-05 2021-07-27 Decode Genetics Ehf método para determinar uma suscetibilidade à arritmia cardíaca ou acidente vascular cerebral em um indivíduo humano, uso de uma sonda de oligonucleotídeo, e, aparelho para determinar um indicador genético para a arritmia cardíaca e/ou acidente vascular cerebral em um indivíduo humano

Also Published As

Publication number Publication date
JP5646174B2 (ja) 2014-12-24
BRPI0720116B8 (pt) 2021-07-27
US20140227693A1 (en) 2014-08-14
EA017529B1 (ru) 2013-01-30
KR20090087494A (ko) 2009-08-17
US20090325163A1 (en) 2009-12-31
EP2121979B1 (en) 2017-07-12
BRPI0720116B1 (pt) 2018-05-02
CA2673123A1 (en) 2008-06-12
CA2673123C (en) 2019-04-30
KR20150113216A (ko) 2015-10-07
AU2007330306B2 (en) 2013-10-24
IL199049A (en) 2014-09-30
MX2009005651A (es) 2009-06-08
AU2007330306A1 (en) 2008-06-12
EP2121979A2 (en) 2009-11-25
US8637244B2 (en) 2014-01-28
NZ577805A (en) 2012-09-28
JP2010511404A (ja) 2010-04-15
WO2008068780A2 (en) 2008-06-12
SG177185A1 (en) 2012-01-30
DK2121979T3 (en) 2017-09-25
BRPI0720116A2 (pt) 2014-01-14
WO2008068780A3 (en) 2008-10-09
KR101582321B1 (ko) 2016-01-05
EA200970578A1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
MX2009005651A (es) Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2009059321A3 (en) Rca locus analysis to assess susceptibility to amd and mpgnii
EP2663656A1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
PE20121029A1 (es) Marcadores de riesgo para enfermedad cardiovascular
NZ591236A (en) Methods for determining a breeding value based on a plurality of genetic markers
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2011087760A3 (en) Processes and kits for identifying aneuploidy
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2010036960A3 (en) Methods for treating, diagnosing, and monitoring lupus
BR112012030813A2 (pt) "métodos e kits para detecção in situ de sequências de nucleotídeo"
WO2010041046A8 (en) Granin proteins as markers of heart disease
WO2009086215A3 (en) Pathway analysis of cell culture phenotypes and uses thereof
WO2008028031A3 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
WO2013090386A3 (en) Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample
WO2013132074A3 (en) A genotyping test for assessing risk of autism
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2009102748A3 (en) Alternatively transcribed genes associated with schizophrenia
WO2012080359A3 (en) Mhc genes and risk of graft versus host disease
WO2007120955A3 (en) Genes affecting human memory performance
WO2009147658A3 (en) Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
AR068526A1 (es) Metodos para identificar variaciones de secuencias de nucleotidos (polimorfismos o mutaciones) en sujetos poliploides mediante un metodo de secuenciacion terminado con un dideoxinucleotido trifosfato (ddntp)
WO2012000119A8 (en) A method of determining a predisposition to atrial fibrillation in a subject

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application